NCT06365788View on ClinicalTrials.gov

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Triple Negative Breast Neoplasms
Interventions
DRUG

Abemaciclib

150 mg tablet orally twice daily

DRUG

Bicalutamide

150 mg tablet orally once daily

Trial Locations (6)

2610

RECRUITING

ZAS Augustinus, Antwerp

Unknown

NOT_YET_RECRUITING

Antwerp University Hospital, Antwerp

RECRUITING

University Hospital Brussels, Brussels

RECRUITING

Ghent University Hospital, Ghent

RECRUITING

Jessa Ziekenhuis, Hasselt

RECRUITING

University Hospitals Leuven, Leuven

All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Teva Pharma

INDUSTRY

lead

Universitaire Ziekenhuizen KU Leuven

OTHER